Parkinson's disease: prospects for improved drug therapy

Trends in Pharmacological Sciences
J J HaganG H Poste

Abstract

L-Dopa has long been the mainstay of therapy for Parkinson's disease but its long-term shortcomings, principally uncoordinated, spasmodic or irregular movements (dyskinesias) and fluctuating control of motor symptoms (on/off fluctuations), are well documented. The postulated neuroprotective properties of L-deprenyl, often used as an adjunct to L-dopa, are under scrutiny and doubts have also been raised regarding its safety. Alternative therapeutic approaches are clearly needed. In this review, Jim Hagan, Derek Middlemiss, Paul Sharpe and George Poste outline some new approaches to treatment, with an emphasis on novel, selective dopamine receptor agonists. In addition, Parkinson's disease is commonly thought to be caused by the neurotoxic effects of an unidentified agent but recent data indicate a greater genetic component than previously recognized. Developments in the genetics of Parkinson's disease may provide the key to the next generation of therapeutics.

References

Dec 1, 1992·Neurology·P JennerC D Marsden
Jan 1, 1991·Pharmacology, Biochemistry, and Behavior·R J EdenA Wright
Nov 9, 1991·Lancet·N ArtsM Horstink
Aug 4, 1990·Lancet·R Howard, D Castle
Aug 4, 1990·Lancet·M J VidailhetY Agid
Jul 1, 1991·Neurology·B J Brew
Mar 1, 1990·Journal of Neurochemistry·A H SchapiraC D Marsden
Mar 1, 1990·Annals of Neurology·L I GolbeR C Duvoisin
Jan 1, 1990·Movement Disorders : Official Journal of the Movement Disorder Society·W G JohnsonR Duvoisin
Jun 24, 1989·Lancet·G BanfieldD Luesley
Jan 1, 1989·Movement Disorders : Official Journal of the Movement Disorder Society·J JankovicC Vander Linden
Jan 1, 1987·Movement Disorders : Official Journal of the Movement Disorder Society·N QuinnC D Marsden
Jan 1, 1987·Journal of Neurology, Neurosurgery, and Psychiatry·C D Marsden
Feb 16, 1967·The New England Journal of Medicine·G C CotziasL M Schiffer
May 1, 1967·Neurology·M M Hoehn, M D Yahr
Nov 1, 1995·Annals of Neurology·C W OlanowJ Esterlitz
Aug 18, 1995·Neuroscience Letters·M Camacho-OchoaM F Piercey
May 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·C E Clarke
Apr 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·S B BluntC D Marsden
Jan 1, 1994·Movement Disorders : Official Journal of the Movement Disorder Society·C W OlanowJ Jankovic
Jun 1, 1994·Neurology·R Alberca, J J Ochoa
Jan 1, 1994·Neurology·S Hocherman, J Aharon-Peretz
Mar 1, 1993·Journal of Neurology, Neurosurgery, and Psychiatry·D Caparros-LefebvreH Petit
Apr 1, 1993·Annals of Neurology·J H KurthJ D Schwankhaus
Nov 1, 1995·Journal of Neurology, Neurosurgery, and Psychiatry·D E Bateman
Feb 1, 1996·Neurology·R YoshiokaP F Chance
Feb 1, 1996·Neurology·C E PringleP Jacob

❮ Previous
Next ❯

Citations

Jan 12, 1999·Mechanisms of Ageing and Development·P BariliF Amenta
Jan 1, 2000·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·D CentonzeG Bernardi
Oct 23, 2010·Nature Chemistry·Chaekyu KimVincent M Rotello
Mar 27, 2002·Biological & Pharmaceutical Bulletin·Yoshihisa KitamuraTakashi Taniguchi
Jul 26, 2005·Experimental Brain Research·Luis F SchettinoHoward Poizner
Mar 13, 2002·Pharmacology, Biochemistry, and Behavior·Vincenzo Di MatteoEnnio Esposito
Jun 19, 2010·CNS Neuroscience & Therapeutics·Giuseppe Di GiovanniVincenzo Di Matteo
Mar 26, 2016·Progress in Neurobiology·Philippe De Deurwaerdère, Giuseppe Di Giovanni
Jul 2, 2003·Journal of Pharmacological Sciences·Yoshihisa KitamuraKenji Watanabe
Jan 17, 2015·Journal of the Neurological Sciences·Michelangelo BartoloFrancesco Pierelli
Sep 2, 2008·Biochimica Et Biophysica Acta·Haeman JangRichard Jay Smeyne
Dec 5, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·E MohrP P De Deyn
Jan 5, 2002·Expert Opinion on Investigational Drugs·B Drukarch, F L van Muiswinkel
Jan 4, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Fatma HaddadRafik Karaman
Mar 1, 2001·Acta Neuropsychiatrica·L LemeyH van den Ameele
Feb 9, 2008·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Antonio Di StefanoLaura Serafina Cerasa
Jun 2, 2018·Progress in Neuro-psychopharmacology & Biological Psychiatry·Clare M Eddy, Jennifer L Cook

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.